Grifols SA (GRFS)
8.89
-0.09
(-1.00%)
USD |
NASDAQ |
Dec 09, 14:56
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 6.050B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 25.03% |
| Valuation | |
| PE Ratio | 14.47 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 0.7273 |
| Price to Book Value | 2.625 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | 0.1734 |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 1.871 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 77.82% |
Profile
| Grifols SA is a global specialty plasma therapeutics company that engages in the development, manufacturing, and distribution of a broad range of biological medicines based on plasma-derived proteins. It operates through the following segments: Biopharma, Diagnostic, Bio Supplies, and Others. The Biopharma Segment includes all activities related with products deriving from human plasma for therapeutic use. The Diagnostic Segment deals with the marketing of diagnostic testing equipment, reagents, and other equipment. The Bio Supplies segment consists of all transactions related to biological products for non-therapeutic use. The Others segment focuses on the rendering of manufacturing services to third party companies. The company was founded by José Antonio Grifols i Roig in 1909 and is headquartered in Barcelona, Spain. |
| URL | http://www.grifols.com |
| Investor Relations URL | https://www.grifols.com/en/presentations-and-events |
| HQ State/Province | Catalonia |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | Feb. 24, 2026 (est.) |
| Last Earnings Release | Jul. 29, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Aug. 12, 2025 |
Ratings
Profile
| Grifols SA is a global specialty plasma therapeutics company that engages in the development, manufacturing, and distribution of a broad range of biological medicines based on plasma-derived proteins. It operates through the following segments: Biopharma, Diagnostic, Bio Supplies, and Others. The Biopharma Segment includes all activities related with products deriving from human plasma for therapeutic use. The Diagnostic Segment deals with the marketing of diagnostic testing equipment, reagents, and other equipment. The Bio Supplies segment consists of all transactions related to biological products for non-therapeutic use. The Others segment focuses on the rendering of manufacturing services to third party companies. The company was founded by José Antonio Grifols i Roig in 1909 and is headquartered in Barcelona, Spain. |
| URL | http://www.grifols.com |
| Investor Relations URL | https://www.grifols.com/en/presentations-and-events |
| HQ State/Province | Catalonia |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | Feb. 24, 2026 (est.) |
| Last Earnings Release | Jul. 29, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Aug. 12, 2025 |